Qiagen N.v.
Could not find a ticker for this position, may be a filing error
A maker of kits and instruments that extract, purify, and analyze DNA, RNA, and proteins from biological samples, QIAGEN's "Sample to Insight" products are used by research labs, hospitals, and forensic scientists around the world. Founded in 1984 in Düsseldorf, Germany, as Diagen by three doctoral students and their professor, it was one of the first biotech spin-offs from a German university. The "Q" in its name comes from "Q-Smaragd," the special resin in its first plasmid-purification kits.
0.50% Convertible Senior Notes due 2023
20-F · Fiscal year ended Dec 31, 2025 · SEC filing ↗
The original filing sections are available below.
A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors MR Risk Factors 27
A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors MR Risk Factors 27
Read original filing text →A. History and Development of the Company MR Business and Operating Environment 6 B. Business Overview MR Conflict Minerals 6 MR Strategy, Business Model and Value Chain 7 APP Government Regulations 203 C. Organizational Structure MR Company Overview 6 EX List of Subsidiaries 22…
A. History and Development of the Company MR Business and Operating Environment 6 B. Business Overview MR Conflict Minerals 6 MR Strategy, Business Model and Value Chain 7 APP Government Regulations 203 C. Organizational Structure MR Company Overview 6 EX List of Subsidiaries 225 D. Property, Plants and Equipment MR Description of Property 22
Read original filing text →A. Operating Results MR Operating Results 43 B. Liquidity and Capital Resources MR Liquidity and Capital Resources 48 C. Research and Development, Patents and Licenses, etc. MR Research and Development 19 MR Intellectual Property, Proprietary Rights and Licenses 20 QIAGEN N.V. |…
A. Operating Results MR Operating Results 43 B. Liquidity and Capital Resources MR Liquidity and Capital Resources 48 C. Research and Development, Patents and Licenses, etc. MR Research and Development 19 MR Intellectual Property, Proprietary Rights and Licenses 20 QIAGEN N.V. | Financial Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 222 Reference Table Form 20-F Item Form 20-F Caption Section Location in this Document Page MR Research and Development 46 Item 5. D. Trend Information MR Operating Results 43 E. Critical Accounting Estimates MR Critical Accounting Estimates 53
Read original filing text →